

viral titer in the liver was lowest among three monkeys, which was consistent with minimal plasma ALT level and liver damage; (ii) yet, Tm5 exhibited highest viremia levels, (iii) the viral RNA levels in PBMCs, spleen and inguinal and intestinal lymph nodes of Tm5 were much greater than others, and (iv) we could detect negative-strand GBV-B RNA from not only liver but also spleen and PBMCs. Supposing that the entire virus in Tm3 plasma ( $3.8 \times 10^8$  GE/ml) was produced in the liver of which RNA titer was highest among tamarins, most of the virus in Tm5 plasma ( $1.3 \times 10^{10}$  GE/ml) should be derived from extrahepatic tissues. Taken together, our data demonstrate preferential dissemination of GBV-B in extrahepatic tissues. In order to further define the cell type(s) in which GBV-B replicates efficiently, *in situ* histological analysis should be needed as indicated in the case of HCV [16].

It was possible that differential lymphotropism among GBV-B-infected tamarins could be due to adaptive mutation in the viral genome. From this point of view, we cloned the viral RNA obtained from plasma and liver; however, we did not find any sequence heterogeneity in the viral genome (data not shown). Furthermore, challenge of Tm5 plasma to naïve tamarins developed typical semi-acute hepatitis with regular viremia and did not reproduce the preferential lymphotropism (data not shown). These results indicate that GBV-B intrinsically has pleiotropism in a host-dependent manner. It is possible that multiple surface molecules in the host cells, which act as alternative receptors, would determine the pleiotropism of GBV-B. It remains to be investigated whether host molecules which are used as receptors for HCV [17] would also be used by GBV-B.

Histopathological studies showed the inflammatory responses in Tm3 and Tm4 livers; especially, the Tm4 liver developed strong degenerative changes, which was consistent with high ALT levels (Fig. 2G,H). Furthermore, the livers of Tm3 and Tm4 showed substantial proportions of apoptotic cells as revealed by greater signals of DNA fragmentation and caspase-3 activation, both of which were popular markers of apoptosis, than those in Tm5 (Fig. 3). It needs to be clarified whether such cytopathic effects could be directly induced by GBV-B infection into hepatocytes or whether effector cytotoxic T lymphocytes would be responsible for the cytopathicity.

#### Acknowledgments

We are grateful to Dr. Jens Bukh for providing pGBB. We also thank Mami Matsuda, Makiko Yahata and Tetsu Shimoji for technical assistance and members of Corporation for Production and Research of Laboratory Primates for the handling and care of the monkeys. This work was supported by a Health and Labour Science Research Grant from the Ministry of Health, Labour, and Welfare, Japan, and from New

Energy and Industrial Technology Development Organization (NEDO) of Japan.

#### References

- [1] V. Agnello, F.G. De Rosa, Extrahepatic disease manifestations of HCV infection, *J. Hepatol.* 40 (2004) 341–352.
- [2] J. Bukh, C.L. Apgar, M. Yanagi, Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent, *Virology* 262 (1999) 470–478.
- [3] A.S. Muerhoff, et al., Genomic organization of GB viruses A and B: two members of the Flaviviridae associated with GB agent hepatitis, *J. Virol.* 69 (1996) 5621–5630.
- [4] J.N. Simons, et al., Identification of two flavivirus-like genomes in the GB hepatitis agent, *Proc. Natl. Acad. Sci. USA.* 92 (1995) 3401–3405.
- [5] A. Martin, F. Bodola, D.V. Sangar, K. Goettge, V. Popov, R. Rijnbrand, R.E. Lanford, S.M. Lemon, Chronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNA, *Proc. Natl. Acad. Sci. USA.* 100 (2003) 9962–9967.
- [6] J.H. Nam, K. Faulk, R.E. Engle, S. Govindarajan, M. St Claire, J. Bukh, In vivo analysis of the 3' untranslated region of GB virus B after in vitro mutagenesis of an infectious cDNA clone: persistent infection in a transfected tamarin, *J. Virol.* 78 (2004) 9389–9399.
- [7] J.R. Jacob, K.C. Lin, B.C. Tennant, K.G. Mansfield, GB virus B infection of the common marmoset (*Callithrix jacchus*) and associated liver pathology, *J. Gen. Virol.* 85 (2004) 2525–2533.
- [8] B. Beames, D. Chavez, B. Guerra, L. Notvall, K.M. Brasky, R.E. Lanford, Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus, *J. Virol.* 74 (2000) 11764–11772.
- [9] T.J. Pilot-Matias, A.S. Muerhoff, J.N. Simons, T.P. Leary, S.L. Buijk, M.L. Chalmers, J.C. Erker, G.J. Dawson, S.M. Desai, I.K. Mushahwar, Identification of antigenic regions in the GB hepatitis viruses GBV-A, GBV-B, and GBV-C, *J. Med. Virol.* 48 (1996) 329–338.
- [10] K. Tsukiyama-Kohara, N. Iizuka, M. Kohara, A. Nomoto, Internal ribosome entry site within hepatitis C virus RNA, *J. Virol.* 66 (1992) 1476–1483.
- [11] R.L. Chaves, J. Graff, A. Normann, B. Flehmig, Specific detection of minus strand hepatitis A virus RNA by Tail-PCR following reverse transcription, *Nucleic Acids Res.* 22 (1994) 1919–1920.
- [12] J. Mellor, G. Haydon, C. Blair, W. Livingstone, P. and Simmonds, Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells, *J. Gen. Virol.* 79 (1998) 705–714.
- [13] H. Akari, S. Bour, S. Kao, A. Adachi, K. Strelbel, The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor kappaB-dependent expression of antiapoptotic factors, *J. Exp. Med.* 194 (2001) 1299–1311.
- [14] A. Sbardellati, E. Scarselli, E. Verschoor, A. De Tomassi, D. Lazzaro, C. Traboni, Generation of infectious and transmissible virions from a GB virus B full-length consensus clone in tamarins, *J. Gen. Virol.* 82 (2001) 2437–2448.
- [15] R.E. Lanford, D. Chavez, L. Notvall, K.M. Brasky, Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia, *Virology* 311 (2003) 72–80.
- [16] E.J. Gowans, Distribution of markers of hepatitis C virus infection throughout the body, *Semin. Liver Dis.* 20 (2000) 85–102.
- [17] L. Cocquerel, C. Voisset, J. Dubuisson, Hepatitis C virus entry: potential receptors and their biological functions, *J. Gen. Virol.* 87 (2006) 1075–1084.